Bicycle Therapeutics plc
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00P0YWPK6
BCYC
Bicycle Therapeutics plc
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Bicycle Therapeutics plc
ISIN
US0887861088
TICKER
BCYC
MIC
XNAS
REUTERS
BCYC.OQ
BLOOMBERG
BCYC US
F&G:
57
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 05.05.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company’s Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement P...
Bicycle Therapeutics
Do., 01.05.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025.
“In the first quarter, we continued to advance our bu...
Bicycle Therapeutics
Di., 29.04.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel...
Bicycle Therapeutics
Mi., 02.04.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducem...
Bicycle Therapeutics
Di., 01.04.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ...
Bicycle Therapeutics
Do., 27.03.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments.
Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chai...
Bicycle Therapeutics
Mi., 05.03.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducem...
Bicycle Therapeutics
Di., 25.02.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates.
“In 2024, the significan...
Bicycle Therapeutics
Mi., 05.02.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at...
Bicycle Therapeutics
Mo., 03.02.2025
Bicycle Therapeutics
US0887861088
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company’s Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induce...
Bicycle Therapeutics
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
